Pharmacoeconomic comparison of ziprasidone with other atypical oral antipsychotic agents in schizophrenia

• DOI: 10.7175/fe.v12i1.96
• Publication Date: 2016-06-13T12:36:38Z
• Authors: Andrea Fagiolini; Alice Matone; Claudio Gaz; Simona Panunzi; Andrea De Gaetano
• Keywords: Ziprasidone; Paliperidone; Akathisia

Objective: to comparatively investigate – by means of computer simulations the economic cost and clinical outcomes five atypical oral antipsychotic agents (ziprasidone, olanzapina, risperidone, paliperidone aripiprazolo).Methods: a cyclical stochastic model representing patient evolution, taking into account main adverse reactions (akathisia, weight gain extra-pyramidal ARs), drug efficacy on psychosis stabilization probability relapse, was developed. Ten different scenarios were compared, each starting with one considered antipsychotics, prescribed either at home or in hospital setting. Switching another medication allowed until no untried drugs available, which case clozapine treatment admission Psychiatric Therapeutic Rehabilitation Center irreversibly assigned. Model inputs probabilities ARs, destabilization (assumed equal for all); as well costs attributable drugs, hospitalization, outpatient care terms concomitant medications. Sources trials reported most recent literature (from year 2000), selected based homogeneity observational period dosage used.Results: scenario, hospitalization represented highest component overall (approximately 67%). Assuming effectiveness, ziprasidone fared better than all other competitors, showing lowest average annual per (and also costs) largest numbers controlled months without reactions, independently initial Conclusions: important determinant total appears be whose is about 600% higher medications cost. Medication effectiveness tolerability remain however utmost importance patients being reduction rate.